y*****l
发帖数: 5997 | 1 This Small Biotech Firm's Shares Could Rocket in the Next 30 Days
By: Anthony Haddad
Staff Writer
StreetAuthority
Published: March 26, 2010
Every year, about a quarter million cases of liver cancer are diagnosed in
the United States; around the world the number is estimated to exceed two
million. According to the American Cancer Society, the five-year survival
rate of liver cancer is just 10.8%. This is one of the most fatal of all
cancers -- prostate (98.4%), breast (88.6%), and even lung can... 阅读全帖 |
|
v**********m
发帖数: 5516 | 2 http://seekingalpha.com/article/894061-delcath-systems-an-exclu
Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst
September 28, 2012 | about: DCTH
Disclosure: I am long DCTH. (More...)
Today I have the pleasure of publishing an exclusive interview that took
place this week between me and one of the leading senior analysts for
medical technology, Mr. Matt Dolan of ROTH Capital Partners. Mr. Dolan has
followed the industry for nearly a decade and has been the senior analys... 阅读全帖 |
|
v**********m
发帖数: 5516 | 3 it's an old news, right? everyone is expecting that; that's the reason it's
stuck at ~1.9-2.0.
I did not see any news coming out today.
-----------------
http://www.delcath.com/news-events/news/20120101/99999999/
Investor News from Reuters
August 15, 2012 - REUTERS
Delcath Submits New Drug Application For Proprietary Chemosaturation System
To The U.S. Food And Drug Administration
August 08, 2012 - REUTERS
Delcath To Present At Upcoming Investor Conferences
August 07, 2012 - REUTERS
Delcath Repor... 阅读全帖 |
|
v**********m
发帖数: 5516 | 4 8/10/2012 5:34 AM ET
(RTTNews) - Having transitioned from a development stage company to a
commercial organization with operational activities in April of this year,
Delcath Systems Inc. (DCTH:Quote) is gearing up to play its part of
NDA resubmission in the upcoming binary event.
The company's shares have lost over 40% of their value year-to-date, and
trade near their 52-week low. With the company scheduled to resubmit the New
Drug Application for its proprietary chemosaturation system
in a coup... 阅读全帖 |
|
f**********g
发帖数: 2252 | 5 I think I got the news.
Delcath Systems signs multi-year supply agreement with Synerx Pharma
Monday 10/18/2010 4:23 AM ET - Datamonitor
Related Companies
Symbol Last %Chg
DCTH 8.37 2.32%
As of 12:07 PM ET 10/20/10
Delcath Systems, Inc., a development stage, specialty pharmaceutical and
medical device company, has signed a multi-year supply agreement with Synerx
Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the
supply of Delcath's branded melphalan hydrochloride for injectio... 阅读全帖 |
|
v**********m
发帖数: 5516 | 6 另外一篇pump文
Delcath seeks FDA approval for chemo device
The Business Review by Barbara Pinckney, Reporter
Date: Friday, August 17, 2012, 2:17pm EDT - Last Modified: Friday, August 17
, 2012, 2:18pm EDT
Enlarge Image
Eamonn Hobbs, CEO of Delcath, said the company has asked the FDA for
priority review status on the company's liver chemotherapy system for sales
in the United States.
Donna Abbott Vlahos | The Business Review
Eamonn Hobbs, CEO of Delcath, said the company has asked the FDA for
priority... 阅读全帖 |
|
v**********m
发帖数: 5516 | 7 觉得MM要开始炒了。
JMP Securities Initiates Coverage on Delcath Systems (DCTH)
Posted by James Brewer on Sep 19th, 2012 // No Comments
Delcath Systems, Inc. logoJMP Securities started coverage on shares of
Delcath Systems (NASDAQ: DCTH) in a research report released on Wednesday
morning. The firm issued an outperform rating and a $4.00 price target on
the stock.
Shares of Delcath Systems opened at 1.82 on Wednesday. Delcath Systems has a
one year low of $1.40 and a one year high of $4.74. The company... 阅读全帖 |
|
v**********m
发帖数: 5516 | 8 本人觉得AF有些扯淡，特别是那个DCTH替FDA说话的那段。AF觉得自己是豪猪吗？还吓
得后颈毛都竖起来。
在AF提供的时间点内可以做做波段。
by- Var.
--------------------------------
D. Jones asks, "Do you have an opinion on Delcath Systems(DCTH)? They are
submitting their NDA [New Drug Application] later this year and I was
wondering if it's time to buy before a potential run-up."
I'm not a Delcath fan, never been one, mainly because of the small
commercial market for the company's Chemosaturation (ChemoSat) liver-tumor
treatment system. I haven't had big concer... 阅读全帖 |
|
y*****l
发帖数: 5997 | 9 Delcath Submits CE Mark Technical File for Hepatic ChemoSAT(TM) Delivery
System
Monday 12/06/2010 6:30 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
DCTH 9.94 0.40%
As of 11:17 AM ET 12/6/10
Delcath Systems, Inc. (Nasdaq: DCTH) today announced that the Company has
submitted its CE Mark Technical File to its European Notified Body to obtain
CE Mark approval for its proprietary chemosaturation system, which the
Company intends to market in the European Union (EU) as the Delcath Hepatic
Ch... 阅读全帖 |
|
v**********m
发帖数: 5516 | 10 如果历史重演，下两周会有10-15% 的小波来迎接FDA的接受信或据信。
如果1）DCTH的管理层不是太猪头，2）这个会议确实再今年1月份开过（我没有再DCTH
公司的网站查到确切的消息），那么FDA非常可能再10月12日或15日宣布给与DCTH快速
审批。
等FDA决定是否接受后，再讨论DCTH的走向;另外千万注意DCTH在等FDA的决定前增发股
票。
各位见好就收。
======
after consultation with a variety of experts and the FDA, we have agreed to
include the addition of the Generation 2 filter in the NDA as a technical
change as part of the CMC or Chemistry, Manufacturing, and Control module.-
Delcath Systems 's CEO Discusses Q2 2012 Results - Earnings Call Transcript
====... 阅读全帖 |
|
|
t**u
发帖数: 1572 | 12 shit, I just buy 1600 share this morning.
Delcath Announces Updated Efficacy Results From Phase 3 Trial of
Chemosaturation for Melanoma Metastases in the Liver Presented at European
Multidisciplinary Cancer Congress
Delcath Systems (NASDAQ:DCTH - News) announced today that James F. Pingpank,
MD, FACS, Associate Professor of Surgery at the University of Pittsburgh
School of Medicine, will present updated investigator results from the Phase
3 randomized trial of Delcath's chemosaturation system wi... 阅读全帖 |
|
v**********m
发帖数: 5516 | 13 NEW YORK, Aug. 15, 2012 /PRNewswire/ — Delcath Systems, Inc. (NASDAQ:DCTH)
announced today that it has submitted a New Drug Application (NDA) to the U.
S. Food and Drug Administration seeking approval for the Company’s
proprietary chemosaturation system for use with melphalan hydrochloride in
the treatment of patients with unresectable metastatic melanoma in the liver
. The Company included its Generation 2 filter in its NDA submission as a
technical change to the Chemistry, Manufacturing, and C... 阅读全帖 |
|
m****g
发帖数: 530 | 14 Delcath公司宣布，FDA已将其Melphalan指定为罕见病治疗药，该药用于治疗那些癌细
胞已扩散到肝脏和胰岛细胞的神
经内分泌肿瘤患者和类癌肿瘤患者。
目前，Delcath正在招募受试者参加Melphalan的一项II期临床实验，检测该药相应
的给药系统，这种系统属于Delcath
经皮肝灌注系统（PHP），针对使用高剂量Melphalan治疗癌细胞已扩散至肝脏的患者。
Delcath公司首席执行官表示，该药再次被FDA指定罕见药物令人欣喜，此前它已两
次被指定为罕见病药物——相应适应
症为转移性黑素瘤和转移性眼黑素瘤。
以高剂量Melphalan治疗神经内分泌癌在即将进行的II期临床实验中将是观察的重
点，这在药物的研发进程中是重要的一
步。 |
|
f**********g
发帖数: 2252 | 15 ONTY almost done. Too crazy this week.
DCTH should be safe to buy at 5, but it won't start to run now.
U can buy when it up with volume.
http://finviz.com/screener.ashx?v=341&t=ONTY,DCTH
Delcath Systems, Inc. Announces the Completion of Common Stock Offering
23 hours 41 minutes ago - PR Newswire via Comtex
PR NewswireDelcath Systems, Inc. (NASDAQ: DCTH) today announced it has
closed its previously announced offering of 5,000,000 common shares at a
price to the public of $5.05 per share. Delcath ... 阅读全帖 |
|
O**I
发帖数: 776 | 16 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
v**********m
发帖数: 5516 | 17 The dilution you mean in this post is this one? I just copied one post from
yahoo. It's not a recent news. It's been there for quite a while. Why it
shall be connected to the AH share price dropping?
-------------------------------------------------
The $100,000,000 includes $62,967,199 of securities
By wcase70 . 20 hours ago . Permalink
that were initially filed on December 29, 2011.
By filing a shelf offering, the company has all the paperwork in order if
and when it wants to sell the stock, d... 阅读全帖 |
|
|
O**I
发帖数: 776 | 19 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 20 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 21 去年的？
http://seekingalpha.com/article/206060-delcath-clinical-results
Notes from Dr Whitman a melanoma physician at ASCO as posted on the internet
about the Delcath talk: "Well, this presentation went very well, I thought.
The data was even better than the intial press release from April. The
hepatic PFS (primary endpoint) was 245 days in the PHP arm and 49 days in
the BAC (best alternative care) arm. There was no survival benefit on an
intent to treat basis BUT (and this point is currently rattl... 阅读全帖 |
|
w******i
发帖数: 1476 | 22 any FA?
DCTH UPDATE 2-Delcath liver cancer treatment found effective Aug 22, 2011
DCTH UPDATE 2-Delcath says colorectal cancer treatment not effective Sep 1,
2011 |
|
|
v**********m
发帖数: 5516 | 24 http://seekingalpha.com/article/901761-interview-delcath-s-ceo-
Yoffe: To close, is Delcath funded well enough to get through all of the
upcoming steps or will the company be looking for additional funding?
Hobbs: Our last quarterly report was for the period ended June 30, 2012. At
that time, our cash balance was approximately $29.3 million. As of June 30th
, we remained debt-free and have a $20 million working capital credit
facility with Silicon Valley Bank that provides us with additional fin... 阅读全帖 |
|
|
c*****r
发帖数: 3 | 26 的确可惜，下午3：40左右出的消息
Delcath Phase III Trial Results Exceed Primary Endpoint Expectations
Treatment Arm Shows More Than 3x Median hPFS Compared to Control Arm
不用后悔，以后赚钱机会很多，biotech stock别错过出消息的时间 |
|
|
w****r
发帖数: 245 | 28 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
|
|
n*********b
发帖数: 140 | 31 栓塞治疗肝癌已经临床应用多年，尤其是在中国。Delcath没有比较或解释为什么
Chemosaturation有可能会有更多的优越性。 |
|
|
|
f**********g
发帖数: 2252 | 34 Bottom 5 Companies in the Health Care Equipment Industry With Relatively Low
Return on Equity (ETRM, DCTH, DXCM, NMTI, CRDC)
Tuesday 10/19/2010 4:42 AM ET - Comtex Smartrend(r)
Related Companies
Symbol Last %Chg
DCTH 8.37 2.32%
DXCM 14.38 1.77%
ETRM 2.31 29.78%
As of 12:06 PM ET 10/20/10
Below are the bottom five companies in the Health Care Equipment industry as
measured by return on equity (ROE). ROE is a general indication of the
company's efficiency; Investors usually look for companies with... 阅读全帖 |
|
y*****l
发帖数: 5997 | 35 AERL, BEXP, DCTH & JAZZ Among Charts to Watch
Thursday 11/11/2010 11:58 AM ET - Advicetrade
Related Companies
Symbol Last %Chg
BEXP 24.94 -2.69%
DCTH 10.39 1.07%
JAZZ 15.14 0.13%
AERL 10.30 -2.55%
As of 9:52 AM ET 11/12/10
AERL, BEXP, DCTH & JAZZ Among Charts to Watch By Harry Boxer,
www.TheTechTrader.com an AdviceTrade.com publication
Asia Entertainment & Resources Ltd. (AERL) has been explosive of late, more
than doubling from just over 5 to not far from 12. Tuesday’s pullback
was follow... 阅读全帖 |
|
|
w*******0
发帖数: 13 | 37 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 38 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
|
t**u
发帖数: 1572 | 40 I just bought 1000 shares today. No drug is perfect.
NEW YORK, May 31, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH - News) announced today that management will present at The Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 12:15 ET in New York. Mr. David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.
I bet there might be some rebounce |
|
w*********7
发帖数: 2883 | 41 Under FDA rules, the agency has 60 days to notify a company about the
acceptance of a new drug application seeking priority review. For Delcath,
that means FDA's "acceptance" decision could be announced by Oct. 14. [Since
that's a Sunday, the company may hear on Friday, Oct. 12 or wait to make an
announcement until Monday, Oct. 15.] |
|
